Ashutosh Pareek, DO
Endocrinology · Salem, MANPI 1285892687
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), gifts and education — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Mannkind Corporation at 58.4% of the total. Among endocrinology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$122
- Amgen$63
- Ardelyx, Inc.$24
What the payments were for
- Food & beverage$10851%
- Education$4320%
- Gifts$5928%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 3 | $122 |
| Amgen | 3 | $63 |
| Ardelyx, Inc. | 1 | $24 |
How this compares
$210 in reported general payments places this provider in the 95th percentile of 82 endocrinology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 511 | $889,230 |
| MounjaroTirzepatide | 289 | $514,738 |
| OzempicSemaglutide | 280 | $357,727 |
| JardianceEmpagliflozin | 217 | $245,176 |
| Tresiba Flextouch U-200Insulin Degludec | 126 | $116,684 |
| FarxigaDapagliflozin Propanediol | 81 | $107,947 |
| JanuviaSitagliptin Phosphate | 74 | $103,210 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 54 | $77,766 |
| TradjentaLinagliptin | 70 | $74,374 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $49,179 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $47,255 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $38,912 |
| Humulin R U-500Insulin Regular, Human | 16 | $35,268 |
| Bydureon BciseExenatide Microspheres | 23 | $34,068 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 248 | $33,413 |
Paid to pharmacies, not to this prescriber.
Other endocrinology in Salem
- Allison CohenSalem$0
- Sarah KanbourBoston$0
- Susan HadenChestnut Hill$0
- Serena MistryMelrose$0
- Shiming XuSpringfield$0
- Linda JaffeBoston$0
- Jae SimBoston$0
- Elizabeth HallBoston$0
- Pamela HartzbandBoston$0
- Mala SivanandyBoston$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.